Reverse transcriptase mutants with multiple mutation sites

By introducing multiple mutations at specific sites of M-MLV enzymes, a high-temperature resistant reverse transcriptase mutant was constructed, which solved the problem of poor thermal stability of reverse transcriptase at high temperatures, significantly improved the reverse transcription efficiency, and through site combination Optimize the comprehensive performance of enzymes.

CN114480330BActive Publication Date: 2024-11-01DAAN GENE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202011269344.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-11-13
Publication Date
2024-11-01
Estimated Expiration
2040-11-13

AI Technical Summary

Technical Problem

The existing murine leukemia reverse transcriptase (M-MLV) has poor thermal stability at high temperatures, affecting the efficiency of reverse transcription. There is uncertainty in existing mutation modification methods and difficult to screen.

Method used

By introducing multiple mutations at specific sites of the M-MLV enzyme, including amino acid residue mutations at sites 446, 313, 583, 607 and 221, a reverse transcriptase mutant that is resistant to high temperature and has high reverse transcription efficiency was constructed, and the patient was given a new study on the M-MLV enzyme. Screening and combining mutation sites improves the thermal stability and activity of the enzyme.

Benefits of technology

The reverse transcription efficiency of reverse transcriptase at high temperatures was significantly improved, and the efficiency of some mutants at 58°C was increased by more than 10 times, which significantly improved the detection efficiency, and further optimized the comprehensive performance of the enzyme by combining mutation sites.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002777135380000051
    Figure BDA0002777135380000051
  • Figure BDA0002777135380000061
    Figure BDA0002777135380000061
  • Figure BDA0002777135380000062
    Figure BDA0002777135380000062
Patent Text Reader

Abstract

The present invention provides a reverse transcriptase mutant with multiple mutation sites. Specifically, the present invention constructs a reverse transcriptase (M-MLV) mutation library, and finally screens out a reverse transcriptase mutant with multiple mutation sites with improved thermal stability and higher amplification efficiency through a large number of screenings. The reverse transcription efficiency is significantly improved compared with the wild-type M-MLV enzyme.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and in particular relates to a reverse transcriptase mutant with multiple mutation sites. Background Art

[0002] Murine leukemia reverse transcriptase (M-MLV) is a DNA polymerase that uses RNA as a template. It has RNase H activity but no 3'-5' exonuclease activity and can be used to synthesize cDNA by reverse transcription. Since RNA has a relatively complex secondary structure, it has a great influence on the reverse transcription efficiency of the M-MLV enzyme. The simplest way to open the secondary structure of RNA is to open the hydrogen bonds of the secondary structure through high temperature, and the RNA becomes a linear single strand. However, the optimal reaction temperature of the wild-type M-MLV enzyme is 37°C, and its stability and activity decrease at high temperatures. Therefore, the main modification direction of the M-MLV enzyme is to improve the thermal stability of the M-MLV enzyme through mutation so that it can adapt to reactions at high temperatures.

[0003] The mutational modification of M-MLV enzyme can be achieved through the following approaches:

[0004] 1. Random mutation. Random mutations are performed on the full-length sequence or a certain domain of M-MLV, and then screened. This method can screen out MMLV mutants with high activity and high thermal stability, but the technical process is complicated and the capacity of the mutation library generated by random mutation can reach 10 7 , accompanied by a large number of inactive mutations, making screening extremely difficult. (Reference: Arezi B, Hogrefe H. Novel mutations in Moloney Murine Leukemia Virus reverse transcriptase increase thermostability through tighter binding to template-primer [J]. Nucleic Acids Research, 2008, 37 (2): 473-481.)

[0005] 2. Site-directed mutagenesis of specific active sites. This method is highly targeted and can improve enzyme activity by increasing the affinity of amino acids at key active sites such as nucleic acid binding sites and metal ion binding sites with substrates. However, this method lacks analysis of the overall structure of the enzyme and cannot improve the stability of the enzyme as a whole. (Reference: Yasukawa K, Mizuno M, Konishi A, et al. Increase in thermal stability of Moloney murine leukaemia virus reverse transcriptase by site-directed mutagenesis [J]. Journal of Biotechnology, 2010, 150 (3): 299-306.)

[0006] In general, due to the complexity of protein structure, not only the amino acids located in the active site but even some amino acids far away from the active site may affect the overall structure and performance of the enzyme. Therefore, there is great uncertainty in enzyme modification. Summary of the invention

[0007] The object of the present invention is to provide a reverse transcriptase mutant which is resistant to high temperature and has high reverse transcription efficiency.

[0008] In the first aspect of the present invention, an M-MLV enzyme mutant is provided, wherein the M-MLV enzyme mutant is mutated at at least two (which may be two, three, four, or five) sites selected from the following group: amino acid residue at position 446, amino acid residue at position 313, amino acid residue at position 583, amino acid residue at position 607, and amino acid residue at position 221, wherein the amino acid residues are numbered as shown in SEQ ID NO.1.

[0009] The amino acid sequence of the corresponding wild-type murine leukemia reverse transcriptase (M-MLV) is shown in SEQ ID NO.1.

[0010] In another preferred embodiment, in the M-MLV enzyme mutant, the amino acid residue at position 446 is mutated to Cys.

[0011] In another preferred embodiment, in the M-MLV enzyme mutant, the amino acid residue at position 313 is mutated to His or Gln.

[0012] In another preferred embodiment, in the M-MLV enzyme mutant, the amino acid residue at position 583 is mutated to Asn.

[0013] In another preferred embodiment, in the M-MLV enzyme mutant, the amino acid residue at position 607 is mutated to Lys.

[0014] In another preferred embodiment, in the M-MLV enzyme mutant, the amino acid residue at position 221 is mutated to Arg.

[0015] In another preferred embodiment, the amino acid sequence of the M-MLV enzyme mutant has at least about 80% homology compared with SEQ ID NO.1; more preferably, it has at least about 90% homology; most preferably, it has at least about 95% homology; such as at least about 96%, 97%, 98%, 99% homology.

[0016] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 583 and amino acid residue 313.

[0017] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 313 and amino acid residue 221.

[0018] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 583 and amino acid residue 446.

[0019] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 583 and amino acid residue 221.

[0020] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 313 and amino acid residue 446.

[0021] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 313 and amino acid residue 607.

[0022] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 313, amino acid residue 583, and amino acid residue 221.

[0023] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 313, amino acid residue 583, and amino acid residue 607.

[0024] In another preferred embodiment, the M-MLV enzyme mutant has mutations at amino acid residue 313, amino acid residue 583, and amino acid residue 446.

[0025] In another preferred embodiment, compared with the wild type, the reverse transcription efficiency of the M-MLV enzyme mutant at high temperature (58° C.) is increased by more than 10 times, preferably more than 20 times, and more preferably more than 30 times.

[0026] The second aspect of the present invention provides a polynucleotide molecule, which encodes the M-MLV enzyme mutant described in the first aspect of the present invention.

[0027] The third aspect of the present invention provides a vector, wherein the vector contains the nucleic acid molecule described in the second aspect of the present invention.

[0028] The fourth aspect of the present invention provides a host cell, wherein the host cell contains the vector described in the first aspect of the present invention or the chromosome is integrated with the nucleic acid molecule described in the second aspect of the present invention.

[0029] In another preferred embodiment, the host cell is a prokaryotic cell or a eukaryotic cell.

[0030] In another preferred embodiment, the prokaryotic cell is Escherichia coli.

[0031] In another preferred embodiment, the eukaryotic cell is a yeast cell.

[0032] The fifth aspect of the present invention provides a method for preparing the M-MLV enzyme mutant according to the first aspect of the present invention, comprising the steps of:

[0033] (i) culturing the host cell according to the fourth aspect of the present invention under suitable conditions, thereby expressing the M-MLV enzyme mutant; and

[0034] (ii) isolating the M-MLV enzyme mutant.

[0035] In another preferred embodiment, the temperature for culturing the host cells in step (i) is 20°C-40°C; preferably 25°C-37°C, such as 35°C.

[0036] The sixth aspect of the present invention provides a kit, which comprises the M-MLV enzyme mutant described in the first aspect of the present invention.

[0037] In another preferred embodiment, the kit further comprises one or more components selected from the following group:

[0038] dNTPs, buffer, primers, probes, and pure water.

[0039] The seventh aspect of the present invention provides use of the M-MLV enzyme mutant described in the first aspect of the present invention in preparing a reverse transcription detection reagent or a reverse transcription kit.

[0040] In an eighth aspect of the present invention, a method for reverse transcription of RNA is provided, the method comprising the steps of:

[0041] (1) Providing a sample containing RNA;

[0042] (2) Reverse transcription reaction

[0043] The reverse transcriptase mutant described in the first aspect of the present invention is used to perform a reverse transcription reaction on the RNA-containing sample provided in step (1).

[0044] In another preferred embodiment, in step (2), the reverse transcription reaction temperature is above 55°C, preferably above 58°C.

[0045] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION

[0046] The inventors have conducted extensive and in-depth research and constructed a reverse transcriptase (M-MLV) mutation library. Through step-by-step screening, mutants with improved thermal stability and higher amplification efficiency were finally screened out. On this basis, the present invention was completed.

[0047] Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can be changed. It should also be understood that the terminology used herein is intended only to describe specific embodiments, and is not intended to be restrictive, and the scope of the present invention will be limited only by the appended claims.

[0048] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. As used herein, the term "about" when used in reference to a specific recited value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0049] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.

[0050] Reverse transcriptase

[0051] Reverse transcriptase is also called RNA-dependent DNA polymerase. The enzyme uses RNA as a template, dNTP as a substrate, and tRNA (mainly tryptophan tRNA) as a primer. At the 3'-OH end of tRNA, according to the principle of base pairing, it synthesizes a single-stranded DNA that is complementary to the RNA template in the 5'-3' direction. This single-stranded DNA is called complementary DNA (cDNA).

[0052] Reverse transcriptase can be used for synthesizing first-strand cDNA, making cDNA probes, RNA transcription, sequencing and reverse transcription of RNA. Commonly used reverse transcriptases in the art include murine leukemia virus (M-MLV) reverse transcriptase and avian myeloblastosis virus (AMV) reverse transcriptase.

[0053] In a preferred embodiment of the present invention, the wild-type M-MLV protein sequence of the present invention is as follows:

[0054] TLNIEDEHRLHETSKEPDVSLGSTWLSDFPQAWAETGGMGLAVRQAPLIIPLKATSTPVSIKQYPMSQEARLGIKPHIQRLLDQGILVPCQSPWNTPLLPVKKPGTNDYRPVQDLREVNKRVEDIHPTVPNPYNLLSGLPPSHQWYTVLDLKDAFFCLRLHPTSQPLFAFEWRDPEMGISGQLTWTRLPQGFKNSPTLFDEALHRDLADFRIQHPDLILLQYVDDLLLAATSELDCQQGTRALLQTLGNLGYRASAKKAQICQKQVKYLGYLLKEGQRWLTEARKETVMGQPTPKTPRQLREFLGTAGFCRLWIPGFAEMAAPLYPLTKTGTLFNWGPDQQKAYQEIKQALLTAPALGLPDLTKPFELFVDEKQGYAKGVLTQKLGPWRRPVAYLSKKLDPVAAGWPPCLRMVAAIAVLTKDAGKLTMGQPLVILAPHAVEALVKQPPDRWLSNARMTHYQALLLDTDRVQFGPVVALNPATLLPLPEEGLQHNCLDILAEAHGTRPDLTDQPLPDADHTWYTDGSSLLQEGQRKAGAAVTTETEVIWAKALPAGTSAQRAELIALTQALKMAEGKKLNVYTDSRYAFATAHIHGEIYRRRGLLTSEGKEIKNKDEILALLKALFLPKRLSIIHCPGHQKGHSAEARGNRMADQAARKAAITETPDTSTLL(SEQ ID NO.:1)

[0055] In a preferred embodiment of the present invention, the codon-optimized wild-type M-MLV DNA sequence (WT) is as follows:

[0056]

[0057] Screening and preparation of mutants

[0058] The present invention calculates the change value (DDG) of the Gibbs free energy change of the enzyme molecule after the single-point mutation, and uses this to measure the change in molecular stability after the mutation. The DDG value (Delta Delta G) is the change value of the Gibbs free energy change of the molecule. The process of protein molecules changing from a normal folded state to a random curled state requires energy consumption, and the value of this energy is the ΔG value. The ΔG value can be used to measure the stability of the protein. The higher the ΔG value, the more energy is consumed for protein denaturation, the higher the temperature at which the protein is denatured, and the more stable the protein is.

[0059] After the protein undergoes site-directed mutation, the interaction between each amino acid changes, causing the ΔG value to change. The difference between the ΔG value of the wild-type protein and the ΔG value of the mutant is the DDG value. If the DDG value is >0, it means that the ΔG value of the mutated protein is lower than that of the wild type, and the protein is more unstable; if the DDG value is <0, it means that the ΔG value of the mutated protein is higher than that of the wild type, and the protein is more stable. Therefore, the DDG value can be used to predict the stability change of the protein structure after site-directed mutation. From a series of mutants, mutations with higher DDG values ​​are selected to construct an MMLV protein mutation library. After expression and purification, the activity and thermal stability of the MMLV after mutation are measured, and single-point mutants with high activity and high thermal stability are screened. However, due to the complexity of the protein structure, it is impossible to obtain mutants that meet the needs of actual applications only through prediction, and in most cases, the simulated predicted mutants will lead to a significant decrease in enzyme activity.

[0060] After a large number of screenings, the present invention screened out 6 mutation sites that can make the M-MLV enzyme high temperature resistant and highly active as follows:

[0061]

[0062] The above six mutation sites were combined to construct 10 MMLV mutants, and MMLV mutants with better performance than the above six single-point mutations were obtained.

[0063] Therefore, in a preferred embodiment of the present invention, the present invention provides an M-MLV enzyme mutant, which undergoes mutations at at least two (which may be two, three, four, or five) sites selected from the following group: amino acid residue at position 446, amino acid residue at position 313, amino acid residue at position 583, amino acid residue at position 607, and amino acid residue at position 221, wherein the amino acid residues are numbered as shown in SEQ ID NO.1.

[0064] In a preferred embodiment, the M-MLV enzyme mutant of the present invention is as follows:

[0065]

[0066] Compared with the wild type, the reverse transcription efficiency of the M-MLV enzyme mutant at high temperature (58° C.) is increased by more than 10 times, preferably more than 20 times, and more preferably more than 30 times.

[0067] In a preferred embodiment, the reverse transcription efficiency test method is as follows:

[0068] Total RNA was extracted from Hela cells as a template and reverse transcription was performed according to the following system

[0069]

[0070]

[0071] The wild-type and mutant MMLV proteins were reacted according to the above system, inactivated at 58°C for 15 minutes and 75°C for 5 minutes; the reverse transcription products were then taken and detected by fluorescence quantitative PCR according to the following system

[0072]

[0073] Q-PCR program: 95°C for 3 minutes, (95°C for 15 seconds, 60°C for 15 seconds, 72°C for 15 seconds to read the fluorescence signal) x 40 cycles.

[0074] Taking the efficiency of wild-type reverse transcriptase as 100%, the reverse transcription efficiency of the mutant is calculated as follows:

[0075] Reverse transcription efficiency = 100% x 2 (Ct 野生型 -Ct 突变型 )

[0076] Among them, the sequence of Random 6 random primer is as follows:

[0077] NNNNNN (N=A or T or G or C)

[0078] The GAPDH-PF primer sequences are as follows:

[0079] GCCTGCTTCACCACCTTCTT(SEQ ID NO.:3)

[0080] The GAPDH-PR primer sequences are as follows:

[0081] TGAACGGGAAGCTCACTGGC(SEQ ID NO.:4)

[0082] A person skilled in the art can obtain the M-MLV enzyme gene sequence of the present invention by conventional methods, such as full artificial synthesis or PCR synthesis. A preferred synthesis method is asymmetric PCR. Asymmetric PCR uses a pair of primers in unequal amounts to produce a large amount of single-stranded DNA (ssDNA) after PCR amplification. This pair of primers is respectively called a non-restricting primer and a restricting primer, and the ratio is generally 50-100:1. In the first 10-15 cycles of the PCR reaction, the amplified product is mainly double-stranded DNA, but when the restricting primer (low concentration primer) is consumed, the PCR guided by the non-restricting primer (high concentration primer) will produce a large amount of single-stranded DNA. The primers used for PCR can be appropriately selected based on the sequence information of the present invention disclosed herein, and can be synthesized by conventional methods. The amplified DNA / RNA fragments can be separated and purified by conventional methods such as by gel electrophoresis.

[0083] The M-MLV enzyme mutant of the present invention can be expressed or produced by conventional recombinant DNA technology, comprising the steps of:

[0084] (1) transforming or transducing a suitable host cell with a polynucleotide encoding the protein of the present invention, or with a recombinant expression vector containing the polynucleotide;

[0085] (2) culturing host cells in a suitable culture medium;

[0086] (3) Isolating and purifying the target protein from the culture medium or cells to obtain the M-MLV enzyme mutant.

[0087] Methods well known to those skilled in the art can be used to construct an expression vector containing the coding DNA sequence of the M-MLV enzyme of the present invention and appropriate transcription / translation control signals, preferably a commercially available vector: pET28. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. The DNA sequence can be effectively linked to an appropriate promoter in the expression vector to guide mRNA synthesis. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator. In addition, the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selecting transformed host cells.

[0088] The recombinant vector includes: a promoter, a target gene and a terminator in the 5' to 3' direction. If necessary, the recombinant vector may also include the following elements: a protein purification tag; a 3' polynucleotide signal; a non-translated nucleic acid sequence; a transport and targeting nucleic acid sequence; a selection marker (antibiotic resistance gene, fluorescent protein, etc.); an enhancer; or an operator.

[0089] Methods for preparing recombinant vectors are well known to those of ordinary skill in the art. Expression vectors can be bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses or other vectors. In short, any plasmid and vector can be used as long as it can replicate and be stable in the host.

[0090] Those skilled in the art can use well-known methods to construct vectors containing the promoter of the present invention and / or the target gene sequence, including in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc.

[0091] The expression vector of the present invention can be used to transform appropriate host cells so that the host transcribes the target RNA or expresses the target protein. The host cell can be a prokaryotic cell, such as Escherichia coli, Corynebacterium glutamicum, Brevibacterium flavum, Streptomyces, Agrobacterium: or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a plant cell. Those skilled in the art are aware of how to select appropriate vectors and host cells. Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism (such as Escherichia coli), it can be treated with the CaCl2 method or electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods (such as microinjection, electroporation, liposome packaging, etc.). Transformation of plants can also be carried out using methods such as Agrobacterium transformation or gene gun transformation, such as leaf disc method, young embryo transformation method, flower bud immersion method, etc. Transformed plant cells, tissues or organs can be regenerated into plants using conventional methods to obtain transgenic plants.

[0092] The term "operably linked" means that the target gene to be transcribed and expressed is linked to its control sequence in a conventional manner in the art so as to be expressed.

[0093] Cultivation of engineered bacteria and fermentation production of target protein

[0094] After obtaining the engineered cells, the engineered cells can be cultured under suitable conditions to express the protein encoded by the gene sequence of the present invention. Depending on the host cells, the culture medium used in the culture can be selected from various conventional culture media, and culture is carried out under conditions suitable for the growth of the host cells. When the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.

[0095] In the present invention, conventional fermentation conditions can be used. Representative conditions include (but are not limited to):

[0096] (a) With regard to temperature, the fermentation and induction temperature of the M-MLV enzyme was maintained at 25-37°C;

[0097] (b) With regard to the pH value during the induction period, the pH value during the induction period is controlled at 3-9;

[0098] (c) As for dissolved oxygen (DO), DO is controlled at 10-90%. The maintenance of dissolved oxygen can be solved by introducing oxygen / air mixed gas;

[0099] (d) As for feed, feed types should preferably include carbon sources such as glycerol, methanol, glucose, etc., which can be fed alone or mixed;

[0100] (e) With regard to the IPTG concentration during the induction period, conventional induction concentrations can be used in the present invention, and the IPTG concentration is usually controlled at 0.1-1.5 mM;

[0101] (f) The induction time is not particularly limited, but is usually 2 to 20 hours, preferably 5 to 15 hours.

[0102] The target protein M-MLV enzyme of the present invention exists in the Escherichia coli cells. The host cells are collected by a centrifuge, and then the host cells are broken by high pressure, machine force, enzymatic cell lysis or other cell breaking methods to release the recombinant protein. The high pressure method is preferred. The host cell lysate can be preliminarily purified by flocculation, salting out, ultrafiltration and other methods and then purified by chromatography, ultrafiltration and the like, or it can be directly purified by chromatography.

[0103] Chromatographic techniques include cation exchange chromatography, anion exchange chromatography, gel filtration chromatography, hydrophobic chromatography, affinity chromatography, etc. Commonly used chromatography methods include:

[0104] 1. Anion exchange chromatography:

[0105] Anion exchange chromatography media include (but are not limited to): Q-Sepharose, DEAE-Sepharose. If the salt concentration of the fermentation sample is high and affects the binding with the ion exchange medium, the salt concentration needs to be reduced before ion exchange chromatography. The sample can be replaced with the equilibrium buffer by dilution, ultrafiltration, dialysis, gel filtration chromatography, etc. until it is similar to the corresponding ion exchange column equilibrium liquid system, and then loaded and subjected to gradient elution of salt concentration or pH.

[0106] 2. Hydrophobic chromatography:

[0107] Hydrophobic chromatography media include (but are not limited to): Phenyl-Sepharose, Butyl-Sepharose, Octyl-Sepharose. The sample is loaded with a salt concentration increased by adding NaCl, (NH4)2SO4, etc., and then eluted by reducing the salt concentration. Impure proteins with large differences in hydrophobicity are removed by hydrophobic chromatography.

[0108] 3. Gel Filtration Chromatography

[0109] Hydrophobic chromatography media include (but are not limited to): Sephacryl, Superdex, Sephadex, etc. The buffer system can be replaced or further purified by gel filtration chromatography.

[0110] 4. Affinity chromatography

[0111] Affinity chromatography media include (but are not limited to): HiTrap TM HeparinHPColumns.

[0112] 5. Membrane filtration

[0113] Ultrafiltration media include: organic membranes such as polysulfone membranes, inorganic membranes such as ceramic membranes, and metal membranes. The purpose of purification and concentration can be achieved through membrane filtration.

[0114] The main advantages of the present invention are:

[0115] (1) The present invention provides a reverse transcriptase mutant that is resistant to high temperatures and has high reverse transcription efficiency.

[0116] (2) The reverse transcriptase mutant with high reverse transcription efficiency of the present invention has significantly improved amplification efficiency compared with the wild-type M-MLV enzyme under the same conditions, thus being able to significantly improve detection efficiency.

[0117] (3) The present invention screened out 6 single-mutation thermostable reverse transcriptase mutants from dozens of mutants through multiple rounds of screening, which were able to maintain a high reverse transcription efficiency at a reverse transcription temperature of 58°C. Moreover, 3 of the thermostable reverse transcriptase mutants could reach reaction equilibrium within 1 minute of reaction time. Therefore, the reverse transcriptase mutants screened by the present invention had unexpectedly excellent technical effects.

[0118] (4) Single mutation sites are combined to obtain a thermostable reverse transcriptase mutant containing multiple mutation sites. Compared with the single mutation reverse transcriptase mutant, the thermostable reverse transcriptase mutant containing multiple mutation sites of the present invention has a further improved reverse transcription efficiency. The combination of advantageous mutation sites helps to improve the comprehensive performance of the M-MLV enzyme.

[0119] The present invention will be further described in detail below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where detailed conditions are not specified are usually carried out according to conventional conditions such as the conditions described in "Molecular Cloning Laboratory Guide" by Sambrook.J et al. (Huang Peitang et al., Beijing: Science Press, 2002), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. The experimental materials and reagents used in the following examples can be obtained from commercial channels unless otherwise specified.

[0120] Example 1 Calculation and screening of DDG values ​​at each site

[0121] The MMLV protein sequence was input into the Rosetta algorithm software Cyrus Bench (Cyrus Biotechnology), and the DDG values ​​of all mutations at positions 0-100, 101-200, 201-300, 301-400, 401-500, 501-600, and 601-671 were calculated. The information of mutation sites with significantly reduced DDG values ​​(DDG values ​​<-2) was obtained as follows:

[0122] Table 1

[0123]

[0124]

[0125] Example 2 Construction of MMLV mutation library

[0126] Based on the above protein sequence, Suzhou Genewise Biotechnology Co., Ltd. performed codon optimization and compiled a DNA sequence (SEQ ID NO.: 2).

[0127] Suzhou Jinweizhi Biotechnology Co., Ltd. performed gene synthesis based on the above DNA sequence, added 5' (NheI) and 3' (XhoI) restriction enzyme sites, cloned the gene into the vector pET28a through 5'NheI and 3'XhoI, constructed plasmid WT-pET28a, prepared recombinant plasmid DNA and glycerol bacteria containing the recombinant plasmid, and performed site-directed mutagenesis on the plasmid WT-pET28a according to the mutation sites involved in Example 1, and constructed mutation libraries Mu1-pET28a to Mu40-pET28a.

[0128] Example 3 Expression and purification of MMLV mutants

[0129] The WT-pET28a and Mu1-40-pET28a plasmids were transformed into BL21 (DE3) competent cells to obtain 37 expression host bacteria, and then transferred to 3 ml LB medium, shaken cultured at 37 ° C for 5 hours, and then 0.1 Mm IPTG was added to induce culture at 18 ° C overnight. The induced bacteria were collected, lysate (50 Mm Tris, 50 Mm NaCl, pH 7.5) was added, ultrasonic lysed, and the supernatant was separated by centrifugation. The supernatant was taken and purified by Ni NTA metal ion chelating filler to obtain wild-type and 40 mutant MMLV proteins.

[0130] Example 4 Screening of mutants

[0131] A: First round of screening (screening for mutations that retain activity)

[0132] Total RNA was extracted from Hela cells as a template and reverse transcription was performed according to the following system

[0133]

[0134] The wild-type and 36 mutant MMLV proteins were reacted according to the above system, inactivated at 42°C for 15 minutes and 75°C for 5 minutes. The reverse transcription products were then taken and detected by fluorescence quantitative PCR according to the following system.

[0135]

[0136] Q-PCR program: 95°C for 3 minutes, (95°C for 15 seconds, 60°C for 15 seconds, 72°C for 15 seconds to read the fluorescence signal) x 40 cycles.

[0137] The results of fluorescent quantitative PCR of the reverse transcription products of each mutant are shown in the following table:

[0138] Table 2

[0139]

[0140] The ct values ​​of the 14 mutants marked with underlines are lower than those of the wild type, which means that the reverse transcription efficiency is higher than that of the wild type. These mutants were selected for the second round of screening.

[0141] B: Second round of screening (screening for high temperature resistant mutations)

[0142] Select the mutants selected in the first round of screening, increase the reverse transcription reaction temperature to 50, 55, and 58°C according to the reverse transcription reaction system of the first round of screening, and then perform reverse transcription efficiency detection according to the fluorescent quantitative PCR system of the first round of screening. The results are as follows:

[0143] Table 3

[0144]

[0145]

[0146] Note: Taking the efficiency of wild-type reverse transcriptase as 100%, the reverse transcription efficiency of mutant is calculated as follows:

[0147] Reverse transcription efficiency = 100% x 2 (Ct 野生型 -Ct 突变型 )

[0148] From the results of the second round of screening, the reverse transcription efficiency of six mutants, Mu_15, 16, 26, 36, 38, and 40, at 58°C was not lower than that at 50°C. These six mutants were selected for the third round of screening.

[0149] C: The third round of screening (screening for mutations with high synthesis rate)

[0150] The mutants selected in the second round of screening were selected, and the reverse transcription reaction system of the first round of screening was used. The reverse transcription reaction temperature was 55°C, and the reaction time was 1 minute, 2 minutes, and 5 minutes. Then, the reverse transcription efficiency was tested according to the fluorescent quantitative PCR system of the first round of screening. The results are as follows:

[0151] Table 4

[0152] Group 1min / ct mean 2min / ct mean 5min / ct mean WT 24.88 22.99 21.85 15 22.24 20.28 19.17 16 20.01 19.25 19.47 26 21.17 20.79 17.72 36 17.64 17.92 17.93 38 21.15 20.73 20.14 40 18.95 19.00 18.34

[0153] From the results of the third round of screening, there was little difference between the 1-minute and 5-minute reverse transcription reactions of Mu_16, 36, and 40, proving that the reaction reached equilibrium after 1 minute.

[0154] Example 5

[0155] In the above examples, six mutation sites that can make the M-MLV enzyme thermostable and highly active were screened out as follows:

[0156]

[0157]

[0158] In this example, the above six mutation sites were combined to construct 10 MMLV mutants, in the hope of obtaining MMLV mutants with better performance than the above six single-point mutations.

[0159] According to the mutation site design in the table below, mutations were made on the wild-type MMLV protein sequence.

[0160] The wild-type MMLV protein sequence is shown in SEQ ID NO.:1.

[0161]

[0162] Based on the above protein sequence, Suzhou Jinweizhi Biotechnology Co., Ltd. performed codon optimization and compiled the DNA sequence. The wild-type MMLV DNA sequence (WT) is shown in SEQ ID NO.:2.

[0163] Suzhou Jinweizhi Biotechnology Co., Ltd. synthesized the gene according to the above DNA sequence, added 5' (NheI) and 3' (XhoI) restriction enzyme sites, cloned the gene into the vector pET28a through 5'NheI and 3'XhoI, constructed the plasmid WT-pET28a, prepared the recombinant plasmid DNA and the glycerol bacteria containing the recombinant plasmid, and carried out site-directed mutagenesis on the plasmid WT-pET28a according to the mutation sites involved, and constructed the mutation libraries Mu41-pET28a to Mu50-pET28a

[0164] Example 6 Expression and purification of MMLV mutants

[0165] The plasmids Mu41 to Mu50-pET28a were transformed into BL21 (DE3) competent cells to obtain 37 expression host bacteria, and then transferred to 3 ml LB medium, shaken cultured at 37 ° C for 5 hours, and then 0.1 Mm IPTG was added to induce culture at 18 ° C overnight. The induced bacteria were collected, lysate (50 Mm Tris, 50 Mm NaCl, pH 7.5) was added, ultrasonic lysed, and the supernatant was separated by centrifugation. The supernatant was taken and purified by Ni NTA metal ion chelating filler to obtain 10 mutant MMLV proteins

[0166] Example 7 Comparison of heat resistance of 10 mutant enzymes and single-point mutant MMLV

[0167] Take 10 mutant enzyme proteins from Mu41 to Mu50 and 6 MMLV mutant enzyme proteins from Mu_15, 16, 26, 36, 38, and 40 at a concentration of 200U / ul, place them in a 50°C constant temperature metal bath for 60 minutes, and heat them in a constant temperature metal bath at 50°C, 55°C, 60°C, 65°C and 70°C for 15 minutes, and then perform reverse transcription reaction with the enzyme sample that has not been heated. Total RNA was extracted from Hela cells as a template, and the reverse transcription reaction system was as follows:

[0168]

[0169] 42℃ for 15 minutes, and inactivated at 95℃ for 5 minutes. Then take the reverse transcription product and perform fluorescence quantitative PCR detection according to the following system

[0170]

[0171] Q-PCR program: 95°C for 3 minutes, (95°C for 15 seconds, 60°C for 15 seconds, 72°C for 15 seconds to read the fluorescence signal) x 40 cycles.

[0172] The results of fluorescence quantitative PCR (Ct value) are shown in the table below:

[0173]

[0174]

[0175] From the above results, it can be seen that the combined mutations Mu_40 to Mu_50 are more stable than single point mutants at temperatures above 55°C. The reverse transcription performance of the enzyme was basically unchanged after treatment at 50°C for 1 hour.

[0176] Example 8 Comparison of reaction rates of 10 mutant enzymes and single-point mutant MMLV

[0177] The reverse transcription reaction was carried out according to the reverse transcription reaction system of Example 7, the reaction temperature was 55°C, the reverse transcription time was 30 seconds, 1 minute, 2 minutes, and 3 minutes, respectively, and the reverse transcription product was detected by fluorescence quantitative PCR, the reaction system was the same as that of Example 3. The Ct value results are as follows:

[0178]

[0179] From the above results, it can be seen that the ct values ​​of Mu_42, Mu_45, Mu_47, Mu_48, and Mu_49 after 1 minute of reaction are basically the same as those after 2 and 3 minutes of reaction, so it is judged that they reach equilibrium after 1 minute of reaction. The ct values ​​of the 10 combined mutants at the same reaction time are all lower than those of single-point mutants, proving that the combination of advantageous mutation sites helps to improve the comprehensive performance of M-MLV enzyme.

[0180] Application of Example 9 in the detection of novel coronavirus nucleic acid

[0181] This embodiment provides the application of the screened combined mutant M-MLV enzyme in the detection reagent of the new coronavirus (2019-nCoV).

[0182] Fluorescence quantitative PCR was used to detect the sequences of the ORF1ab gene and N gene of the 2019-nCoV virus. The primer and probe sequence information used are as follows:

[0183] Target 1(ORF1ab):

[0184] Forward primer (F): CCCTGTGGGTTTTACACTTAA (SEQ ID NO.: 5)

[0185] Reverse primer (R): ACGATTGTGCATCAGCTGA (SEQ ID NO.: 6)

[0186] Fluorescent probe (P): 5'-FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3' (SEQ ID NO.: 7)

[0187] Target 2(N):

[0188] Forward primer (F): GGGGAACTTCTCCTGCTAGAAT (SEQ ID NO.: 8)

[0189] Reverse primer (R): CAGACATTTTGCTCTCAAGCTG (SEQ ID NO.: 9)

[0190] Fluorescent probe (P): 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3' (SEQ ID NO.: 10)

[0191] The reaction system was prepared as follows:

[0192]

[0193] After the reaction system was prepared, the RT-PCR reaction was performed as follows: 55°C for 5 minutes, 95°C for 2 minutes, (95°C for 30 seconds; 68°C for 1 minute to read the fluorescence) × 40 cycles. The results are as follows:

[0194]

[0195] The ct differences (ΔCt) between the five combined mutant enzymes and the wild-type M-MLV enzyme were compared, and the differences in the amplification efficiency of ORF1ab and N genes compared with the wild-type M-MLV enzyme were calculated as follows:

[0196]

[0197] Judging from the Ct values ​​of the amplification of the new coronavirus reference samples by different combinations of mutant MMLV and wild-type M-MLV enzymes, the amplification efficiency of the mutants is significantly higher than that of the wild type. Therefore, the sensitivity of new coronavirus detection can be significantly improved.

[0198] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application. Sequence Listing <110> Sun Yat-sen University Daan Gene Co., Ltd. <120> Reverse transcriptase mutants with multiple mutation sites <130> 0000759 <160> 10 <170> SIPOSequenceListing 1.0 <210> 1 <211> 671 <212> PRT <213> Murine leukemia virus <400> 1 Thr Leu Asn Ile Glu Asp Glu His Arg Leu His Glu Thr Ser Lys Glu 1 5 10 15 Pro Asp Val Ser Leu Gly Ser Thr Trp Leu Ser Asp Phe Pro Gln Ala 20 25 30 Trp Ala Glu Thr Gly Gly Met Gly Leu Ala Val Arg Gln Ala Pro Leu 35 40 45 Ile Ile Pro Leu Lys Ala Thr Ser Thr Pro Val Ser Ile Lys Gln Tyr 50 55 60 Pro Met Ser Gln Glu Ala Arg Leu Gly Ile Lys Pro His Ile Gln Arg 65 70 75 80 Leu Leu Asp Gln Gly Ile Leu Val Pro Cys Gln Ser Pro Trp Asn Thr 85 90 95 Pro Leu Leu Pro Val Lys Lys Pro Gly Thr Asn Asp Tyr Arg Pro Val 100 105 110 Gln Asp Leu Arg Glu Val Asn Lys Arg Val Glu Asp Ile His Pro Thr 115 120 125 Val Pro Asn Pro Tyr Asn Leu Leu Ser Gly Leu Pro Pro Ser His Gln 130 135 140 Trp Tyr Thr Val Leu Asp Leu Lys Asp Ala Phe Phe Cys Leu Arg Leu 145 150 155 160 His Pro Thr Ser Gln Pro Leu Phe Ala Phe Glu Trp Arg Asp Pro Glu 165 170 175 Met Gly Ile Ser Gly Gln Leu Thr Trp Thr Arg Leu Pro Gln Gly Phe 180 185 190 Lys Asn Ser Pro Thr Leu Phe Asp Glu Ala Leu His Arg Asp Leu Ala 195 200 205 Asp Phe Arg Ile Gln His Pro Asp Leu Ile Leu Leu Gln Tyr Val Asp 210 215 220 Asp Leu Leu Leu Ala Ala Thr Ser Glu Leu Asp Cys Gln Gln Gly Thr 225 230 235 240 Arg Ala Leu Leu Gln Thr Leu Gly Asn Leu Gly Tyr Arg Ala Ser Ala 245 250 255 Lys Lys Ala Gln Ile Cys Gln Lys Gln Val Lys Tyr Leu Gly Tyr Leu 260 265 270 Leu Lys Glu Gly Gln Arg Trp Leu Thr Glu Ala Arg Lys Glu Thr Val 275 280 285 Met Gly Gln Pro Thr Pro Lys Thr Pro Arg Gln Leu Arg Glu Phe Leu 290 295 300 Gly Thr Ala Gly Phe Cys Arg Leu Trp Ile Pro Gly Phe Ala Glu Met 305 310 315 320 Ala Ala Pro Leu Tyr Pro Leu Thr Lys Thr Gly Thr Leu Phe Asn Trp 325 330 335 Gly Pro Asp Gln Gln Lys Ala Tyr Gln Glu Ile Lys Gln Ala Leu Leu 340 345 350 Thr Ala Pro Ala Leu Gly Leu Pro Asp Leu Thr Lys Pro Phe Glu Leu 355 360 365 Phe Val Asp Glu Lys Gln Gly Tyr Ala Lys Gly Val Leu Thr Gln Lys 370 375 380 Leu Gly Pro Trp Arg Arg Pro Val Ala Tyr Leu Ser Lys Lys Leu Asp 385 390 395 400 Pro Val Ala Ala Gly Trp Pro Pro Cys Leu Arg Met Val Ala Ala Ile 405 410 415 Ala Val Leu Thr Lys Asp Ala Gly Lys Leu Thr Met Gly Gln Pro Leu 420 425 430 Val Ile Leu Ala Pro His Ala Val Glu Ala Leu Val Lys Gln Pro Pro 435 440 445 Asp Arg Trp Leu Ser Asn Ala Arg Met Thr His Tyr Gln Ala Leu Leu 450 455 460 Leu Asp Thr Asp Arg Val Gln Phe Gly Pro Val Val Ala Leu Asn Pro 465 470 475 480 Ala Thr Leu Leu Pro Leu Pro Glu Glu Gly Leu Gln His Asn Cys Leu 485 490 495 Asp Ile Leu Ala Glu Ala His Gly Thr Arg Pro Asp Leu Thr Asp Gln 500 505 510 Pro Leu Pro Asp Ala Asp His Thr Trp Tyr Thr Asp Gly Ser Ser Leu 515 520 525 Leu Gln Glu Gly Gln Arg Lys Ala Gly Ala Ala Val Thr Thr Glu Thr 530 535 540 Glu Val Ile Trp Ala Lys Ala Leu Pro Ala Gly Thr Ser Ala Gln Arg 545 550 555 560 Ala Glu Leu Ile Ala Leu Thr Gln Ala Leu Lys Met Ala Glu Gly Lys 565 570 575 Lys Leu Asn Val Tyr Thr Asp Ser Arg Tyr Ala Phe Ala Thr Ala His 580 585 590 Ile His Gly Glu Ile Tyr Arg Arg Arg Gly Leu Leu Thr Ser Glu Gly 595 600 605 Lys Glu Ile Lys Asn Lys Asp Glu Ile Leu Ala Leu Leu Lys Ala Leu 610 615 620 Phe Leu Pro Lys Arg Leu Ser Ile Ile His Cys Pro Gly His Gln Lys 625 630 635 640 Gly His Ser Ala Glu Ala Arg Gly Asn Arg Met Ala Asp Gln Ala Ala 645 650 655 Arg Lys Ala Ala Ile Thr Glu Thr Pro Asp Thr Ser Thr Leu Leu 660 665 670 <210> 2 <211> 2013 <212> DNA <213> Artificial sequence <400> 2 acgctgaata tcgaggacga acaccgtctg cacgaaacca gcaaggagcc ggacgttagt 60 ctgggtagca cgtggctgag cgattttcca caagcgtggg cggaaaccgg tggtatgggt 120 ctcgccgttc gccaagcccc actcattatc ccactgaaag ccacgagcac gccggtgagc 180 atcaagcagt acccgatgag ccaagaagcc cgcctcggca ttaaaccgca tattcagcgt 240 ctgctgggacc aaggcattct ggtgccgtgc cagagtccgt ggaatacgcc actgctcccg 300 gttaagaagc cgggcaccaa cgattatcgc ccggttcaag acctccgcga agtgaacaag 360 cgcgtggaag atatccatcc gaccgtgcca aatccgtaca atctgctgag tggcctcccg 420 ccgagtcatc aatggtacac cgtgctggat ctcaaggatg cgttttctg cctccgtctg 480 catccaacca gccagccact ctttgcgttt gagtggcgcg acccagaaat gggtatcagc 540 ggtcaactga cgtggacgcg tctgccgcaa ggcttcaaaa acagcccgac gctgttcgat 600 gaggccctcc atcgcgatct ggcggatttc cgtatccagc atccagatct gattctgctg 660 footcgttg acgatctgct cctcgcggcc accagtgaac tggattgcca gcaaggtacc 720 cgtgcgctgc tgcagacgct gggcaatctg ggctaccgtg ccagcgcgaa aaaggcgcaa 780 atctgccaga agcaagttaa gtacctcggt tatctgctga aagagggtca acgctggctg 840 accgaggcgc gtaaagagac cgttatgggt cagccaacgc caaagacgcc acgccagctc 900 cgcgaatttc tgggtaccgc cggcttctgt cgtctgtgga ttccgggctt cgcgggaaatg 960 gcggcgccac tctacccgct gaccaaaacc ggtaccctct tcaattgggg cccagatcag 1020 cagaaggcct accaagaaat taaacaagcg ctgctcaccg cgccggccct cggtctccca 1080 gatctgacca aaccgtttga gctgttcgtg gacgagaagc aaggctacgc caaaggcgtg 1140 ctgacccaga aactcggtcc atggcgtcgt ccggtggcct acctcagtaa gaaactggat 1200 ccagttgcgg cgggttggcc gccatgtctc cgtatggtgg cggcgattgc cgttctgacc 1260 aaagacgccg gcaaactcac catgggtcag ccgctggtta ttctcgcccc acatgcggtg 1320 gaagcgctgg ttaaacaacc gccagaccgc tggctgagca atgcccgcat gacccattat 1380 caagcgctgc tgctggacac cgaccgcgtt cagttcggtc cggtggttgc gctgaatcca 1440 gcgacgctgc tgccgctgcc agaagaaggt ctgcagcaca actgtctgga cattctggcc 1500 gaggcccatg gcacccgtcc agatctcacc gatcagccac tgccagacgc cgatcatacg 1560 tggtacaccg atggtagtag tctgctgcaa gaaggtcaac gtaaagcggg tgccgcggtg 1620 acgacggaaa ccgaggtgat ctgggccaaa gcgctgccag cgggtaccag cgcgcaacgt 1680 gcggaactga tcgcgctgac ccaagcgctc aaaatggccg agggcaagaa actcaacgtg tacaccgaca gtcgctacgc gtttgcgacc gcgcacatcc acggtgagat ttatcgccgc cgtggtctgc tcacgagcga aggtaaggag atcaagaata aggacgagat cctcgcgctg ctgaaagccc tctttctgcc gaaacgtctg agcatcatcc attgcccggg tcaccagaag ggccacagtg cggaagcgcg cggtaatcgc atggccgatc aagccgcgcg caaagcggcg attack ccccggatac gagcacgctg ctg <210> 3 <211> 20 <212> DNA <213> Artificial sequence (Artificial sequence) <400> 3 gcctgcttca ccaccttctt <210> 4 <211> 20 <212> DNA <213> Artificial sequence (Artificial sequence) <400> 4 tgaacggga gctcactggc <210> 5 <211> 21 <212> DNA <213> Artificial sequence (Artificial sequence) <400> 5 ccctgtgggt tttacactta a <210> 6 <211> 19 <212> DNA <213> Artificial sequence <400> 6 acgattgtgc atcagctga 19 <210> 7 <211> 28 <212> DNA <213> Artificial sequence <400> 7 ccgtctgcgg tatgtggaaa ggttatgg 28 <210> 8 <211> twenty two <212> DNA <213> Artificial sequence <400> 8 ggggaacttc tcctgctaga at 22 <210> 9 <211> twenty two <212> DNA <213> Artificial sequence <400> 9 cagacatttt gctctcaagc tg 22 <210> 10 <211> 20 <212> DNA <213> Artificial sequence <400> 10 ttgctgctgc ttgacagatt 20

Claims

1. A M-MLV enzyme mutant, characterized in that: The M-MLV enzyme mutant undergoes mutations at the 313th amino acid residue, the 583rd amino acid residue, and the 607th amino acid residue in the sequence shown in SEQ ID NO.1; and the 313th amino acid residue site mutates to Gln, the 583rd amino acid residue site mutates to Asn, and the 607th amino acid residue site mutates to Lys.

2. A polynucleotide molecule, characterized in that The polynucleotide molecule encodes the M-MLV enzyme mutant according to claim 1.

3. A carrier, characterized in that The vector contains the polynucleotide molecule according to claim 2.

4. A host cell, characterized in that The host cell contains the vector of claim 3 or the chromosome is integrated with the polynucleotide molecule of claim 2.

5. The host cell according to claim 4, characterized in that The host cell is a prokaryotic cell or a eukaryotic cell.

6. A kit, characterized in that: The kit comprises the M-MLV enzyme mutant according to claim 1.

7. A method for preparing the M-MLV enzyme mutant according to claim 1, comprising the steps of: (i) culturing the host cell of claim 4 under suitable conditions to express the M-MLV enzyme mutant; and (ii) isolating the M-MLV enzyme mutant.

8. Use of the M-MLV enzyme mutant according to claim 1 in preparing a reverse transcription detection reagent or a reverse transcription kit.

9. A method for reverse transcription of RNA, characterized in that: The method comprises the steps of: (1) Providing samples containing RNA; (2) Reverse transcription reaction: The M-MLV enzyme mutant according to claim 1 is used to perform a reverse transcription reaction on the RNA-containing sample provided in step (1).